Amoxicillin for Pneumonia
What You Need to Know Before You Apply
What is the purpose of this trial?
The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).
Who Is on the Research Team?
Jocelyn Gravel, MD
Principal Investigator
Sainte-Justine Hospital
Are You a Good Fit for This Trial?
This trial is for children aged 3 months to 18 years with non-severe community acquired pneumonia, showing symptoms like cough, fever, and abnormal breath sounds. They must have signs of pneumonia on a chest X-ray. Kids with severe allergic reactions to amoxicillin, chronic illnesses, or recent hospital stays are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a twice-daily or thrice-daily regimen of amoxicillin for non-severe community acquired pneumonia
Follow-up
Participants are monitored for treatment failure, adverse events, and clinical recurrence
What Are the Treatments Tested in This Trial?
Interventions
- Amoxicillin
Amoxicillin is already approved in European Union, United States, Canada for the following indications:
- Bacterial infections
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Ear, nose and throat infections
- Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract
- Bacterial infections
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
Find a Clinic Near You
Who Is Running the Clinical Trial?
St. Justine's Hospital
Lead Sponsor